J&J in Talks to Sell Hip and Knee Business to Apollo for $20 Billion

Johnson & Johnson (J&J) is in talks to sell its orthopedics hip and knee business to private equity firm Apollo for approximately $20 billion. According to sources close to the matter, the deal has not yet been finalized and there is a possibility that the negotiations could fail. J&J's hip and knee implant business is part of the company's medical device portfolio. This potential sale is seen as part of J&J's strategy to restructure its medical device unit. In recent years, the company has been divesting certain business lines to focus on areas with higher growth potential. Apollo Global Management is a private equity firm with significant investments in the healthcare sector. If the deal goes through, Apollo will add a major orthopedics business to its healthcare portfolio. The $20 billion sale price reflects the market value of J&J's hip and knee business. However, the final value and terms of the deal have not yet been clarified. A different structure or price may emerge in the later stages of the negotiations. This news is interpreted as an indication of J&J's efforts to optimize its medical device business. The company aims to invest in more profitable and growth-oriented areas. On Apollo's side, it is noted that such an acquisition could be a strategic move due to the long-term return potential in the healthcare sector. Not investment advice.